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was 173.8  117.3 days, with no stroke or death, but there was 1 TIA
and 3 major bleeding.
CONCLUSIONS In our early Canadian experience, WATCHMAN for
LAA closure in patients contraindicated to anticoagulation is safe and
effective.
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BACKGROUND Percutaneous left atrial appendage (LAA) closure is
increasingly performed as an alternative to oral anticoagulation (OAC)
in patients with nonvalvular atrial ﬁbrillation (AF). We sought to
evaluate the cost-effectiveness of treating OAC contraindicated pa-
tients with the Amplatzer Cardiac Plug (ACP) device as compared to
aspirin alone.
METHODS A probabilistic patient-level Markov microsimulation
model with a lifetime horizon was performed to assess the discounted
lifetime costs, quality-adjusted life years (QALYs) and incremental
cost-effectiveness ratio of ACP compared to aspirin for AF patients
with contraindications to OAC. Baseline characteristics of the popu-
lation were based upon a published multi-center Canadian ACP
experience for patients at high stroke-risk (CHA2DS2-VASc) and OAC
contraindications. Clinical events included stroke, bleeding, myocar-
dial infarction, and procedure-related complications. Event-rates for
stroke and bleeding were based on the CHA2DS2-VASc and HASBLED
scores. The relative efﬁcacy of ACP and aspirin, as well as utility
scores, were obtained from the published literature. Canadian pro-
cedural and long-term costs were obtained from the Ontario Case
Costing Initiative and the Ontario Ministry of Health and Long Term
Care.
RESULTS Aspirin was less effective than LAA closure with ACP (4.26
 0.52 QALYs versus 4.69  0.33, respectively). The average dis-
counted lifetime cost was $30,830  11,726 for ACP and $39,751 
18,943 for aspirin. Thus, ACP was the dominant option, in that it was
both more effective and less expensive. Our results were robust with a
relatively modest degree of uncertainty, as ACP was the preferred
option in over 90% of simulations at a willingness-to-pay threshold of
$50,000 (ﬁgure).
CONCLUSIONS LAA closure is a novel stroke preventative therapy for
nonvalvular AF and is a cost-effective alternative to aspirin in patients
with contraindications to OAC.
CATEGORIES STRUCTURAL: Left Atrial Appendage Exclusion
KEYWORDS Atrial appendage closure, Atrial ﬁbrillation, LAATCT-729
Percutaneous left atrial appendage closure in patients with non-valvular
atrial ﬁbrillation with Watchman left atrial appendage device: single
center experience and results up to three years follow-up
Jiangtao Dr. Yu,1 Shaofeng Guan,2 Horst Huemmer,1 Fanzhou Cheng,3
László Halmàgyi,1 Manuela Muenzel,1 Thorsten Keil,1
Erich Duenninger1
1Helmut-Walther-Klinikum, Lichtenfels, Germany; 2Shanghai Chest
Hospital, Shanghai, China; 3Luohu People hospital, Shengzhen, China
BACKGROUND Percutaneous left atrial appendage closure (LAAC) has
been although recognized as a new interventional routine, but the
clinical experience with large number of patients from single hospital
without cardiac surgery was worldwide very little. We evaluate pa-
tient selection, safety, feasibility, and midterm results of LAAC with
Watchman left atrial appendage (LAA) device in a single usual hos-
pital without onsite cardiac surgery backup.
METHODS A retrospective review of LAAC cases with Watchman
LAA device in our hospital between February 2012 and April 2015.
Demographic, echocardiographic, procedural, and clinical follow-up
data were collected and analyzed.
RESULTS LAAC was performed using Watchman device in 181 non-
valvular atrialﬁbrillation (NVAF)patientswith long-termoral anticoagulants
(OAC) contraindication. Mean age at closurewas 74.757.78 (range from 47-
92 years), 72.9% male. Hypertension, coronary artery disease, and diabetes
werepresent in71.9%,61.3%,and27.1%patients, respectively.MeanCHADS2
,CHA2DS-VASc and HASBLED scores were 2.21.1, 3.61.4 and 3.61.0,
respectively. Success rate of device implantation was 96.1% (93% in ﬁrst 90
cases, 99% in the second 91 cases) and associated with no major procedural
complications except one case of pericardial tamponade. Two Watchman
left atrial appendage devices were successful implanted in 3 cases due to
atypical anatomy of LAA. At least two transesophageal echocardiography
were performed in the ﬁrst 6 weeks and 6 months after LAAC, respectively.
Followupwas achieved in 92.5% patients and collected over amean follow-
up period of 266 days (range: 34 days to 3.0 years). No device related death
was recorded. At the most recent follow-up, almost all patients were
receiving antiplatelet therapy. Ischemic stroke/transient Ischemic attackwas
observed at an annual rate of 1.6% and the annual rate of any thromboem-
bolic (TE) event was 3.1%. Annual rate of major bleeding was 1.6%
CONCLUSIONS LAAC is a safe and effective stroke prevention therapy
in NVAF patients in a single usual hospital without onsite cardiac
surgery backup both at implantation and during short and midterm
follow-up periods and remarkable improvement of success rate can be
achieved with the increase of the experience of operators. A low
number of TE events was recorded during follow-up.
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BACKGROUND In left atrial appendage occlusion procedures, echo-
cardiography provides guidance for transseptal puncture, sizing and
device implantation and is utilized to assess occlusion grade. Most
cases of LAA closure are performed under general anesthesia and TEE
for guidance. ICE is used for guidance of interventional procedures,
however LAA visualization from the right atrium is often limited. The
aimof this studywas to assess the feasibility of LAAocclusion under ICE
guidance from the left atrium, conscious sedation and local anesthesia.
METHODS From October 2012 to June 2015, in one tertiary care center
in Montreal, 49 consecutive patients (mean age 758y) with AF and
long-term contraindication for anticoagulation underwent LAA
closure under local anesthesia, conscious sedation and ICE guidance
from the left atrium. The ICE catheter and device delivery sheaths
were advanced into the LA through separated ICE-guided transseptal
punctures. Baseline characteristics, procedural and follow-up data
were prospectively recorded. Procedural success was deﬁned as the
implantation of the closure device with adequate occlusion (grade 3
by angiography and<3 by ICE).
